Astrazeneca (AZN) Price to Sales (2009 - 2026)

Astrazeneca has reported Price to Sales for 18 years, with the latest figure at 19.1 in Q2 2026.

• On a quarterly basis, Price to Sales rose 27.43% year-over-year to 19.1 in Q2 2026; TTM through Jun 2026 was 4.8, a 22.99% increase from a year earlier, with the FY2025 full-year figure at 4.86, up 27.17% from the prior year.
• Price to Sales was 19.1 for Q2 2026 at Astrazeneca, down from 20.1 in the prior quarter.
• The five-year high for Price to Sales was 20.36 in Q2 2023, with the low at 6.43 in Q4 2023.
• Average Price to Sales over 5 years is 17.24, with a median of 18.22 recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Price to Sales tumbled 65.69% in 2023, then soared 124.53% in 2024.
• Over 5 years, Price to Sales stood at 18.73 in 2022, then sank by 65.69% to 6.43 in 2023, then surged by 124.53% to 14.43 in 2024, then rose by 27.44% to 18.39 in 2025, then advanced by 3.89% to 19.1 in 2026.
• The last three Price to Sales figures came in at 19.1 (Q2 2026), 20.1 (Q1 2026), and 18.39 (Q4 2025), per Business Quant data.